<DOC>
	<DOCNO>NCT02753569</DOCNO>
	<brief_summary>This feasibility study aim ass potential functional imaging biomarkers ( 18FDG PET-CT DW-MRI ) differentiate immunotherapy induced inflammation , indicative response non-response patient stage IV non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Imaging NSCLC Treatment Response Immunotherapy</brief_title>
	<detailed_description>30 patient , recruit within PEAR Study ( Phase 1 dose escalation palliative radiotherapy anti-PD1 antibody pembrolizumab thoracic tumour ) scan receive immunotherapy NSCLC . Immunotherapy induce change tumour ADC DW-MRI ( surrogate apoptotic tumour cell death ) compare change near contemporaneous , anatomically co-registered 18FDG PET-CT SUV ( non-specific marker GLUT expression hence metabolic activity tumour tumour infiltrating lymphocyte ) . For treatment response , increase ADC ( reflect apoptosis within tumour ) expect , 18FDG uptake expect decrease compare baseline tumour uptake . In presence significant inflammatory cell recruitment , investigator hypothesise similar increase ADC DW-MRI without associate reduction 18FDG PET-CT SUV . Thus relationship ADC change DW-MRI 18FDG change distinguish response non-response presence inflammation .</detailed_description>
	<criteria>Recruited PEAR : Phase 1 dose escalation palliative radiotherapy antiPD1 antibody pembrolizumab thoracic tumour Study MRI incompatible metal implant Claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>PET/CT</keyword>
	<keyword>non-small cell lung cancer</keyword>
</DOC>